ProtFI, an efficient frailty-trained proteomics-based biomarker of aging, robustly predicts age-related decline
Swier Garst (TU Delft - Electrical Engineering, Mathematics and Computer Science, Leiden University Medical Center)
Lieke Kuiper (Rijksinstituut voor Volksgezondheid en Milieu, Erasmus MC, TU Delft - Electrical Engineering, Mathematics and Computer Science)
Erik van den Akker (Leiden University Medical Center, TU Delft - Electrical Engineering, Mathematics and Computer Science)
Niels van den Berg (Leiden University Medical Center)
Mohsen Ghanbari (Erasmus MC)
Simon Mooijaart (Leiden University Medical Center)
Marian Beekman (Leiden University Medical Center)
Marcel Reinders (TU Delft - Electrical Engineering, Mathematics and Computer Science)
P. Eline Slagboom (Leiden University Medical Center)
Joyce van Meurs (Erasmus MC)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Many molecular aging biomarkers have been developed to capture heterogeneity in individual aging rates. Yet, systematic comparison of the modeling choices underlying these biomarkers has been limited. In this study, we trained aging biomarkers on the Rockwood frailty index (FI) and all-cause mortality using UK Biobank Olink proteomics and metabolomics (1H-NMR) data (n = 40,696). We systematically established the impact of model choice, target outcome, and molecular data source on several age-related outcomes. From this, we developed two aging biomarkers, ProteinFrailty (ProtFI) and ProteinMortality (ProtMort), which are both ElasticNet models that use a minimal set of proteins to predict FI and mortality, respectively. In particular, ProtFI outperformed established aging biomarkers in relation to diverse outcomes, including incident cardiovascular disease, handgrip strength, and self-rated health, both in internal validation and two Dutch external cohorts (n = 995, n = 500). Our findings show that an efficient frailty-trained proteomic biomarker robustly predicts age-related decline.